Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 18

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
 or tumor associated antigens or cancer neoantigens and a delivery system.
The delivery system is designed to protect the DNA or mRNA from degradation and promote trafficking into cells and through intracellular
compartments. We designed the delivery system by chemically modifying the low molecular weight polymer to improve its gene transfer activity
without increasing toxicity. We believe that our non-viral DNA technology may be a viable alternative to current approaches to gene delivery
due to several distinguishing characteristics, including enhanced molecular versatility that allows for complex modifications to potentially
improve activity and safety.

The biocompatibility of these polymers reduces the
risk of adverse immune response, thus allowing for repeated administration. Compared to naked DNA or cationic lipids, we believe that
our delivery systems are generally more efficient, cost effective and have a more favorable safety profile. We believe that these advantages
place Imunon in a position to capitalize on this technology platform.

14

THERAPLAS MODALITY: IMNN-001 DEVELOPMENT
PROGRAM

Ovarian Cancer Overview

Ovarian cancer is the most lethal of gynecological
malignancies among women with more than 60% of women dying within five years of diagnosis. This poor outcome is due in part to the lack
of effective prevention and early detection strategies. There were approximately 20,000 new cases of ovarian cancer in the U.S. in 2021
with an estimated 13,000 deaths. Mortality rates for ovarian cancer declined very little in the last 40 years due to the unavailability
of detection tests and improved treatments. Most women with ovarian cancer are not diagnosed until Stages III or IV, when the disease
has spread outside the pelvis to the abdomen and areas beyond, causing swelling and pain. With the five-year survival rates for Stages
III and IV at 41% and 20%, respectively, there remains a need for a therapy that not only reduces the recurrence rate but also meaningfully
improves overall survival. Patients whose cancer recurs or progresses after initially responding to surgery and first-line chemotherapy
have been divided into one of the two groups based on the time from completion of platinum therapy to disease recurrence or progression.
This time period is referred to as platinum-free interval. The platinum-sensitive group has a platinum-free interval of longer than six
months. This group generally responds to additional treatment with platinum-based therapies. The platinum resistant group has a platinum-free
interval of shorter than six months and is resistant to additional platinum-based treatments